Anrong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anrong Wang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Danyu Chen
Department of Gastroenterology and Hepatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication- Danyu Chen
Institute of Digestive Disease and Department of Medicine and Therapeutics State Key Laboratory of Digestive Disease Li Ka Shing Institute of Health Sciences The Chinese University of Hong Kong Hong Kong Hong Kong SAR China
1 shared publication Dongqin Zhao
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication- Guojie Bai
Department of Radiology, Tianjin Beichen Traditional Chinese Medicine Hospital, Tianjin, China
1 shared publication Henrik Nilsson
Division of Surgery, Department of Clinical Sciences, Karolinska Institutet at Danderyd Hospital, Stockholm, Sweden
1 shared publicationJianhua Xu
Department of General Surgery, Songshan Hospital, Chongqing, China
1 shared publication
Latest Publications
- Open Access
- 17 January 2023
- Published by Springer Nature in La radiologia medica
- Vol. 128 (2) , 136-148
Systematic review of machine learning-based radiomics approach for predicting microsatellite instability status in colorectal cancer
This study aimed to systematically summarize the performance of the machine learning-based radiomics models in the prediction of microsatellite instability (MSI) in patients with colorectal cancer (CRC). It was conducted according to the preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA) guideline and was registered at the PROSPERO website with an identifier CRD42022295787. Systematic literature searching was conducted in databases of PubMed, Embase, Web of Science, and Cochrane Library up to November 10, 2022. Research which applied radiomics analysis on preoperative CT/MRI/PET-CT images for predicting the MSI status in CRC patients with no history of anti-tumor therapies was eligible. The radiomics quality score (RQS) and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) were applied to evaluate the research quality (full score 100%). Twelve studies with 4,320 patients were included. All studies were retrospective, and only four had an external validation cohort. The median incidence of MSI was 19% (range 8–34%). The area under the receiver operator curve of the models ranged from 0.78 to 0.96 (median 0.83) in the external validation cohort. The median sensitivity was 0.76 (range 0.32–1.00), and the median specificity was 0.87 (range 0.69–1.00). The median RQS score was 38% (range 14–50%), and half of the studies showed high risk in patient selection as evaluated by QUADAS-2. In conclusion, while radiomics based on pretreatment imaging modalities had a high performance in the prediction of MSI status in CRC, so far it does not appear to be ready for clinical use due to insufficient methodological quality.
- 17 January 2023
- Published by Springer Nature in La radiologia medica
- Vol. 128 (2) , 136-148
Open AccessSystematic review of machine learning-based radiomics approach for predicting microsatellite instability status in colorectal cancer
This study aimed to systematically summarize the performance of the machine learning-based radiomics models in the prediction of microsatellite instability (MSI) in patients with colorectal cancer (CRC). It was conducted according to the preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA) guideline and was registered at the PROSPERO website with an identifier CRD42022295787. Systematic literature searching was conducted in databases of PubMed, Embase, Web of Science, and Cochrane Library up to November 10, 2022. Research which applied radiomics analysis on preoperative CT/MRI/PET-CT images for predicting the MSI status in CRC patients with no history of anti-tumor therapies was eligible. The radiomics quality score (RQS) and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) were applied to evaluate the research quality (full score 100%). Twelve studies with 4,320 patients were included. All studies were retrospective, and only four had an external validation cohort. The median incidence of MSI was 19% (range 8–34%). The area under the receiver operator curve of the models ranged from 0.78 to 0.96 (median 0.83) in the external validation cohort. The median sensitivity was 0.76 (range 0.32–1.00), and the median specificity was 0.87 (range 0.69–1.00). The median RQS score was 38% (range 14–50%), and half of the studies showed high risk in patient selection as evaluated by QUADAS-2. In conclusion, while radiomics based on pretreatment imaging modalities had a high performance in the prediction of MSI status in CRC, so far it does not appear to be ready for clinical use due to insufficient methodological quality.